

An Evolving Frontier – Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting

Seoul, South Korea

Sunday, November 5, 2023



Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.



Faculty



Ramez Eskander, MD


UC San Diego Moores Comprehensive Cancer Center, USA

Anna Fagotti, MD, PhD

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Italy

Stephanie Lheureux, MD, PhD

Princess Margaret Cancer Centre, Canada



Agenda

Welcome & Introductions

Ramez Eskander, MD, UC San Diego Moores Comprehensive Cancer Center, USA

The Evolving Treatment Landscape for The Management of Endometrial Cancer

Ramez Eskander, MD, UC San Diego Moores Comprehensive Cancer Center, USA

Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib


Stephanie Lheureux, MD, PhD, Princess Margaret Cancer Centre, Canada

Disparities in Endometrial Cancer Outcomes, What More Can We Do?

Anna Fagotti, MD, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Italy

Discussion & Wrap Up

All Faculty



Learning Objectives

- Review the current landscape for the treatment of advanced stage or recurrent endometrial cancer.
- Understand common adverse events associated with novel therapies and review mitigation/management strategies.
- Adopt an evidence-based approach to implement treatment options into practice for recurrent endometrial cancer patients.
- Understand treatment sequencing and the data regarding immune check point inhibition rechallenge.
- Identify disparities in endometrial cancer care and patients and learn what can be done to address these issues.

